Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study evaluated hair tonic and gel formulations containing Angiopteris evecta root water extract and found both fulfilled pharmaceutical preparation standards, with the 12.5% hair tonic and 10.0% gel concentrations most effective for hair growth without a significant difference in performance.

This study found that Camellia sinensis (tea) extracts may protect hair from UV-induced damage and color change, with efficacy linked to higher concentrations of key compounds like catechins.

Low levels of ferritin and vitamin B12 are common in women with telogen effluvium, but the link between nutrient deficiencies and the condition is not clear.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

This article reviews various factors contributing to telogen effluvium and examines potential treatments like Minoxidil, but reports no new clinical findings.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

In this study, researchers observed that deficiency in biochemical markers, notably ferritin and serum iron, is frequently found in female patients diagnosed with telogen effluvium, suggesting these tests are crucial in understanding and treating the condition.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study reported that seed germination and root hair growth were significantly enhanced after exposure to an individual whose depression was treated with Emotional Freedom Techniques, suggesting that human mood may influence seed viability.

In this study, researchers piloted an asynchronous telemedicine program for isotretinoin management in acne patients, finding that dosing outcomes were similar to synchronous visits and clinicians were comfortable adjusting doses remotely.

This article discusses the rise of direct-to-consumer teledermatology platforms, warning that they might cause overdiagnosis, overtreatment, and fragmented healthcare, and emphasizes the need for patient counseling about these risks and benefits.

This study suggests that chest, arm, leg, and beard hair samples may be viable alternatives to scalp hair for monitoring long-term alcohol intake, although body hair is more typically collected from men.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

5% ET-02 is a more effective and safe treatment for hair loss than current options.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

This abstract provides a general overview of telogen effluvium as a prevalent cause of hair loss, especially among women, but presents no new research findings.

Mutations in the TSPEAR gene cause a new form of ectodermal dysplasia affecting hair and tooth development.

This study describes teledermatology as a cost-effective and convenient alternative to in-person dermatology consultations during the COVID-19 pandemic, with diagnostic accuracy ranging from 54% to 88%.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.